[go: up one dir, main page]

IL145800A0 - Immunotheraphy of cancer through expression of truncated tumor of tumor-associated antigen - Google Patents

Immunotheraphy of cancer through expression of truncated tumor of tumor-associated antigen

Info

Publication number
IL145800A0
IL145800A0 IL14580099A IL14580099A IL145800A0 IL 145800 A0 IL145800 A0 IL 145800A0 IL 14580099 A IL14580099 A IL 14580099A IL 14580099 A IL14580099 A IL 14580099A IL 145800 A0 IL145800 A0 IL 145800A0
Authority
IL
Israel
Prior art keywords
tumor
immunotheraphy
cancer
expression
associated antigen
Prior art date
Application number
IL14580099A
Other languages
English (en)
Inventor
Milcho S Mincheff
Dmitri I Loukinouv
Serguei Zoubak
Original Assignee
American Foundation For Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Foundation For Biolog filed Critical American Foundation For Biolog
Publication of IL145800A0 publication Critical patent/IL145800A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14580099A 1998-09-30 1999-09-09 Immunotheraphy of cancer through expression of truncated tumor of tumor-associated antigen IL145800A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/164,034 US6387888B1 (en) 1998-09-30 1998-09-30 Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
PCT/US1999/020508 WO2000018933A1 (fr) 1998-09-30 1999-09-09 Immunotherapie anticancereuse par expression d'un antigene tronque specifique d'une tumeur ou associe a une tumeur

Publications (1)

Publication Number Publication Date
IL145800A0 true IL145800A0 (en) 2002-07-25

Family

ID=22592693

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14580099A IL145800A0 (en) 1998-09-30 1999-09-09 Immunotheraphy of cancer through expression of truncated tumor of tumor-associated antigen

Country Status (7)

Country Link
US (1) US6387888B1 (fr)
AU (1) AU5911999A (fr)
BG (1) BG106028A (fr)
CA (1) CA2368856A1 (fr)
IL (1) IL145800A0 (fr)
WO (1) WO2000018933A1 (fr)
ZA (1) ZA200108175B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20060024301A1 (en) * 1997-02-25 2006-02-02 Corixa Corporation Prostate-specific polypeptides and fusion polypeptides thereof
US7517952B1 (en) * 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6897062B1 (en) * 1999-04-09 2005-05-24 Sloan-Kettering Institute For Cancer Research DNA encoding the prostate-specific membrane antigen-like gene and uses thereof
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
AU2001294181A1 (en) * 2000-10-05 2002-04-15 Takeda Chemical Industries Ltd. Novel protein, process for producing the same and use thereof
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
CA2443138A1 (fr) * 2001-03-30 2002-10-10 The Regents Of The University Of California Anticorps monocatenaires diriges contre muc-1 pour le ciblage d'une tumeur
WO2003008537A2 (fr) * 2001-04-06 2003-01-30 Mannkind Corporation Sequences d'epitope
US7731648B2 (en) * 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en) * 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7951061B2 (en) * 2001-07-25 2011-05-31 Allan Foreman Devices for targeted delivery of thermotherapy, and methods related thereto
AU2002326961A1 (en) * 2001-10-10 2003-04-22 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP2360169B1 (fr) * 2001-10-23 2015-10-14 Psma Development Company, L.L.C. Anticorps contre le PSMA
AU2003219983A1 (en) * 2002-03-01 2003-09-16 Applied Immune Technologies Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens
ITMN20020013A1 (it) 2002-04-04 2003-10-06 Amfag Spa Doccia estraibile da cucina
US20040156846A1 (en) * 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
AU2003222173A1 (en) * 2003-04-01 2004-11-23 Patrick J. Branigan Nucleic acid compositions and methods for use
US7541035B2 (en) * 2003-06-05 2009-06-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides for the treatment of prostate and breast cancer
AU2004249254B2 (en) * 2003-06-17 2010-07-08 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
JP2007202490A (ja) * 2006-02-02 2007-08-16 National Institute Of Advanced Industrial & Technology 動物細胞用新規発現ベクター
KR100896483B1 (ko) 2007-07-13 2009-05-08 연세대학교 산학협력단 Ｉｌ-12 및 4-1ｂｂｌ을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물
WO2009046739A1 (fr) * 2007-10-09 2009-04-16 Curevac Gmbh Composition pour traiter le cancer de la prostate (pca)
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
US8565892B2 (en) * 2009-10-31 2013-10-22 Qteris, Inc. Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment
SI2580243T1 (sl) 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
CA2802782C (fr) 2010-06-15 2018-03-13 Genmab A/S Conjugues anticorps humain-medicament contre le facteur tissulaire
JP5504510B2 (ja) * 2012-02-20 2014-05-28 独立行政法人産業技術総合研究所 動物細胞用新規発現ベクター
CN104619349B (zh) 2012-06-07 2018-07-10 Ambrx公司 前列腺特异性膜抗原抗体药物结合物
WO2013188740A1 (fr) 2012-06-14 2013-12-19 Ambrx, Inc. Anticorps anti-psma conjugués à des polypeptides de ligand de récepteur nucléaire
AU2016355191B2 (en) 2015-11-18 2023-06-29 Orbis Health Solutions Llc T7 alpha viral vector system

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861589A (en) 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
US5013645A (en) 1987-04-14 1991-05-07 Abbott Laboratories Immunological methods and materials for detection of tumor associated antigens
US5660834A (en) 1988-03-11 1997-08-26 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with carbohydrate-carrier conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5045320A (en) 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
US5773215A (en) 1989-10-24 1998-06-30 Board Of Regents, The University Of Texas System Tumor marker protein for cancer risk assessment
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5227471A (en) 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
WO1993020185A1 (fr) 1992-04-01 1993-10-14 Steinman Ralph M Procede permettant de faire proliferer in vitro des precurseurs de cellules dendritiques et utilisation de celles-ci pour produire des immunogenes
WO1994009820A1 (fr) 1992-11-05 1994-05-11 Sloan-Kettering Institute For Cancer Research Antigene de membrane specifique a la prostate
JPH08509606A (ja) 1993-04-20 1996-10-15 ロビンソン，ウィリアム エス． 細胞内感染因子に感染した個体を処置する方法および物質
IT1264516B1 (it) 1993-05-31 1996-09-24 Biotop Sas Di Rita Cassarin Cellule dendritiche immortalizzate
JPH09504000A (ja) 1993-08-11 1997-04-22 ジェナー テクノロジーズ 前立腺癌ワクチン
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5985847A (en) 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
US5935818A (en) 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
CO4600637A1 (es) 1996-03-15 1998-05-08 Corixa Corp Compuestos para inmunoterapia e inmunodiagnosis del cancer de prostata

Also Published As

Publication number Publication date
BG106028A (bg) 2002-12-29
CA2368856A1 (fr) 2000-04-06
WO2000018933A1 (fr) 2000-04-06
US6387888B1 (en) 2002-05-14
AU5911999A (en) 2000-04-17
ZA200108175B (en) 2003-01-06

Similar Documents

Publication Publication Date Title
IL145800A0 (en) Immunotheraphy of cancer through expression of truncated tumor of tumor-associated antigen
IL131539A0 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
HUP0002095A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
IL140845A0 (en) Compositions for therapy and diagnosis of prostate cancer
GB2318734B (en) Methods of preventing breast cancer
IL136167A0 (en) Conjugates useful in the treatment of prostate cancer
AU2948199A (en) Breast cancer antigen
AU9689398A (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
GB9804065D0 (en) Tumour associated antigen 791Tgp72
GB9703633D0 (en) Cancer therapy
SI1140147T1 (sl) Terapija s hcg za zdravljenje metastatskega raka na dojki
GB9819999D0 (en) Treatment of cancer
AUPO851597A0 (en) Treatment of prostate cancer
ZA981585B (en) Compounds for immunotherapy of prostate cancer and methods for their use
EP1107665A4 (fr) Procede de diagnostic du cancer de la prostate
ZA981536B (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
GB9624800D0 (en) Methods of preventing breast cancer
IL142311A0 (en) Methods and compositions for the diagnosis and therapy of prostate cancer
AU6536898A (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
ZA972238B (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer.
SI1157041T1 (sl) Protitelesa za terapijo in diagnozo raka
AU8719298A (en) Treatment of prostate cancer
AU6404000A (en) Evaluation of adenocarcinoma of the prostate and breast using anti-dystroglycan antibodies
GB9701876D0 (en) Cancer therapy